Related Experiment Video
Updated: Sep 18, 2025
Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
Published on: May 9, 2019
Anti-osteoporosis Activity of Sodium Glucuronate in Preosteo-blast MC3T3-E1 Cells and an Ovariectomized Rat Model
Anqi Wang1,2, Biyao Liu1,2, Qingkai Zeng2,3
1College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250000, China.
Abstract:
The purpose of this study was to explore the potential therapeutic effect of sodium glucuronate (SG) on osteoporosis (OP). To achieve this aim, the optimal concentration of SG for stimulating MC3T3-E1 osteoblast cells derived from the calvaria of neonatal mice was determined using cell counting kit-8 and alkaline phosphatase (ALP) activity assays. Osteogenic markers were analyzed by qRT-PCR and Western blotting. The histopathological morphology of the tibial tissues was performed using hematoxylin and eosin staining. The levels of bone turnover markers (BTMs) were assessed using enzyme-linked immunosorbent assay (ELISA). SG treatment was found to effectively promote osteoblastic differentiation and mineralization in MC3T3-E1 cells, evidenced by enhanced ALP activity, increased calcium deposition, and upregulated expression of key osteogenic markers including runt-related transcription factor 2 (RUNX2), osteocalcin (OCN), and osteopontin (OPN). Moreover, in ovariectomized rats, a model of postmenopausal OP, SG treatment significantly promoted bone formation, regulated the levels of BTMs, and augmented bone mineral density. Consistently, SG upregulated the expression of osteogenic genes (RUNX2, OCN, and OPN) in bone tissue, further supporting its osteogenic potential. Collectively, these findings suggest that SG possesses the ability to stimulate bone formation and may hold promise as a potential agent for the management of OP.
Insights
Sodium glucuronate (SG) promotes osteoblast activity and bone formation. This study suggests SG may be a promising therapeutic agent for managing osteoporosis.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Osteoporosis (OP) is a significant skeletal disorder characterized by decreased bone mass and increased fracture risk.
- Current treatments for OP have limitations, necessitating the exploration of novel therapeutic agents.
- Sodium glucuronate (SG) is being investigated for its potential bone-protective effects.
Purpose of the Study:
- To evaluate the therapeutic potential of sodium glucuronate (SG) in promoting osteoblast differentiation and bone formation.
- To determine the optimal concentration of SG for stimulating MC3T3-E1 osteoblast cells.
- To assess the efficacy of SG in an ovariectomized rat model of osteoporosis.
Main Methods:
- Cell counting kit-8 and alkaline phosphatase (ALP) assays were used to assess osteoblast viability and activity.
- Quantitative real-time PCR (qRT-PCR) and Western blotting analyzed osteogenic marker expression.
- Hematoxylin and eosin staining evaluated tibial tissue morphology in ovariectomized rats.
- Enzyme-linked immunosorbent assay (ELISA) measured bone turnover markers (BTMs).
Main Results:
- SG significantly enhanced ALP activity, calcium deposition, and the expression of osteogenic markers (RUNX2, OCN, OPN) in osteoblast cells.
- In ovariectomized rats, SG treatment increased bone mineral density and bone formation.
- SG modulated BTMs and upregulated osteogenic gene expression in bone tissue.
Conclusions:
- Sodium glucuronate demonstrates significant osteogenic potential by promoting osteoblast differentiation and bone formation.
- SG effectively improved bone parameters in an osteoporosis model.
- These findings support SG as a potential therapeutic candidate for osteoporosis management.
